Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results

Circulation. 1997 Jul 1;96(1):128-36. doi: 10.1161/01.cir.96.1.128.

Abstract

Background: Treatment of calcified (in contrast to simple) lesions with PTCA has been associated with a lower success rate and more procedural complications. Rotablation can improve acute results, but the high restenosis rate remains a problem. The purpose of this study was to evaluate the clinical and angiographic outcome of patients with complex and calcified lesions treated with a combination of rotablation and stenting.

Methods and results: Seventy-five consecutive patients with 106 lesions had rotablation prior to coronary stenting. Intravascular ultrasound-guided stenting was used without subsequent anticoagulation in 93% of patients. Procedural success was achieved in 93.4% of lesions. Acute stent thrombosis occurred in two lesions (1.9%), and subacute stent thrombosis in one lesion (0.9%). Angiographic follow-up was performed in 82.5% of lesions at 4.6 +/- 1.9 months with an angiographic restenosis rate of 22.5%. Clinical follow-up was performed in all patients at 6.4 +/- 3 months; target lesion revascularization was needed in 18% of lesions; Q-wave myocardial infarction occurred in 1.3%, coronary bypass surgery in 4.0%, and death in 1.3%.

Conclusions: Optimal coronary stenting after rotablation in calcified and complex lesions can be performed with a high success rate, an acceptable rate of procedural complications, and a low rate of stent thrombosis. This approach was associated with a low incidence of angiographic restenosis compared with results usually obtained with other interventional strategies in calcified and complex lesion subsets.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Aspirin / administration & dosage
  • Atherectomy, Coronary*
  • Calcinosis / diagnostic imaging
  • Calcinosis / therapy*
  • Coronary Angiography
  • Coronary Disease / diagnostic imaging
  • Coronary Disease / therapy*
  • Coronary Thrombosis / etiology
  • Female
  • Fibrinolytic Agents / administration & dosage
  • Follow-Up Studies
  • Heparin / administration & dosage
  • Humans
  • Male
  • Middle Aged
  • Recurrence
  • Retrospective Studies
  • Stents* / adverse effects
  • Ticlopidine / administration & dosage
  • Ultrasonography
  • Warfarin / administration & dosage

Substances

  • Fibrinolytic Agents
  • Warfarin
  • Heparin
  • Ticlopidine
  • Aspirin